Forside  
Velg data du ønsker med i utskriften
Tittel Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne blodsykdommer, 2020
  • Engelsk tittel -
  • Versjon -
  • Status - Publisert
  • IS-nr - 2930
  • ISBN - ISBN- 978-82-8081-619-1
  • DOI -
  • Revisjonsdato - 15.06.2020
  • Neste revisjon -
  • Publikasjonsdato - 09.07.2012
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Jens Hammerstrøm et al
  • Publikasjonstype - Nasjonale retningslinjer
Vedlegg
 
  1. Cortelazzo S, Ponzoni M, Ferreri AJM, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2011;79(3):330-43.

  2. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166-78.

  3. Gokbuget N, Hoelzer D. Treatment of Adult Acute Lymphoblastic Leukemia. Semin Hematol 2009;46(1):64-75.

  4. Evensen SA, Brinch L, Tjønnfjord GE, Stavem P, Wisløff F. Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia. Br J Haematol 1994;88(1):88-93.

  5. Tangen JM, Fløisand Y, Haukås E, Næss IA, Skjelbakken T, Stapnes C, et al. Overlevelse hos voksne med akutt lymfoblastisk leukemi. Tidsskr Nor Lægeforen 2010;130(17):1710-3.

  6. Tjønnfjord GE, Gedde-Dahl T, Heldal D, Brinch L. Treatment outcome in adults with acute lymphoblastic leukemia: 50% long-term disease-free survival. Leukemia 2007;21(10):2203-4.

  7. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;American Society of Hematology. Education Program. 2010:21-9.

  8. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol 2009;27(6):911-8.

  9. Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CG, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): Early results of U.S. intergroup trial C10403. Abstract. Blood 2014;124(21):796.

  10. Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallböök H, Heyman M, et al. Toxicity profile and treatment delays in NOPHO ALL2008 – comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol 2015 Apr 13, Epub ahead of print.

  11. Martell MP, Atenafu EG, Minden MD, Schuh AC, Yee KWL, Schimmer AD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol 2013;163:458-64.

  12. Gökbuget N. How I treat older patients with ALL. Blood 2013;122(8):1366-75.

  13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al., red. WHO classification of tumours of haematopoietic and lymphoid tissue. 4 utg. Lyon: IARC; 2008.

  14. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29(5):532-43.

  15. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010;150(4):389-405.

  16. Rowe JM. Optimal management of adults with ALL. Br J Haematol 2009;144(4):468-83.

  17. Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomized controlled trial. Lancet Oncol 2014;15(8):809-18.

  18. Briscot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 2015;100(3):392-99.

  19. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112(4):1005-12.

  20. Marks DI. Treating the "older" adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;American Society of Hematology. Education Program. 2010:13-20.

  21. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89(3):282-7.      

  22. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2011;117(8):1583-94.

  23. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: Systematic review and meta-analysis. Cancer 2010;116(14):3447-57.

  24. Goldstone AH, Rowe JM. Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program 2009;593-601.

  25. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer. rev utg. Oslo: Helsedirektoratet; 2012. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-maligne-lymfomer

  26. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.Cancer 2004;101(12):2788-801.